The FDA put both companies on an import alert, which lets it stop their products at the US border, News Nation reports.
Recap by typeshit. Full story at News Nation on MSN.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Avi Roy explains why only about 1% to 2% of the semaglutide tablet reaches the blood, while most of a starting Foundayo dose does.
Patients regained 5.1% of weight after the one-time endoscopic procedure versus 8.2% with sham, keeping about 80% of their GLP-1 weight loss, per trial data.
Loading…